Drugs / Augmentin
Augmentin
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05724628 | Oct → Nov 2023 | appendicitis | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT04198129 | Oct 2020 → Jan 2022 | infectious disease | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT03935828 | Jun 2019 → Dec 2020 | chronic rhinosinusitis, poisoning | United States Naval Medical Center, San Diego | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00185939 | Aug 2003 → Nov 2005 | infectious disease | Stanford University | Completed | No outcome recorded |
| Phase 43 trials · 1 missed | ||||||
| Phase 4 | NCT05925179 | Aug → Oct 2023 | tooth erosion, non-bacterial | Biruni University | Unknown | No outcome recorded |
| Phase 4 | NCT04573504 | Sep 2020 → Sep 2024 | — | Northwestern University | Unknown | No outcome recorded |
| Phase 4 | NCT03228108 | Apr 2018 → Sep 2021 | infectious disease, prostate cancer | Radboud University Medical Center | Completed | Missed primary |
| Phase not applicable2 trials · 1 missed | ||||||
| — | NCT02189668 | Jul 2014 → Jul 2015 | appendicitis | Peter Minneci | Terminated | Missed primary |
| — | NCT00520949 | Oct 2006 → Jun 2008 | — | Aga Khan University | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 0 | NCT05100654 Comparator | Apr 2022 → Dec 2027 expected | erectile dysfunction, prosthesis-related infectious disease | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02431832 Background | Feb → Oct 2015 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01963442 Comparator | Nov 2013 → Jun 2018 | — | Versailles Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03333408 Comparator | Jun 2018 → Dec 2024 | — | Our Lady of the Lake Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01825408 Comparator | Feb 2013 → Jun 2014 | sinusitis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT05804123 Background | Oct 2021 → Apr 2024 | respiratory tract infectious disorder | Anabio R&D | Completed | No outcome recorded |
| — | NCT04751500 Comparator | Jan 2021 → Nov 2022 | — | Birmingham Women's and Children's NHS Foundation Trust | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | augmentin | “For oral antibiotics, the choices providers will be given include: Augmentin 500 mg every 12 hours” NCT03935828 ↗15“Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin” NCT05724628 ↗ “Augmentin” NCT04751500 ↗ |
| Known as | Amoxicillin Clavulinate | “Augmentin is the trade name and the generic is Amoxicillin Clavulinate or clavulinic acid.” NCT04198129 ↗ |
| Known as | Amoxicillin-clavulanic | “Augmentin (Amoxicillin-clavulanic)” NCT00520949 ↗ |
| Route | Oral | “oral amoxicillin 1 g plus clavulanate 125 mg three times a day” PMID 33773631 ↗ Mar 2021 |